Login / Signup

What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials.

Richard A FurieEric F MorandIan N BruceDavid Alan IsenbergRonald van VollenhovenGabriel AbreuLilia PinedaRaj Tummala
Published in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
BICLA response is associated with clinical benefit in SLE assessments, PROs, and medical resource utilization, confirming its value as a clinical trial end point that is associated with measures important to patient care.
Keyphrases
  • phase iii
  • systemic lupus erythematosus
  • clinical trial
  • disease activity
  • open label
  • phase ii
  • double blind
  • healthcare
  • rheumatoid arthritis
  • placebo controlled
  • study protocol